Replies to post #91314 on Cytodyn Inc (CYDY)

[justdafactss]

For the 2nd (and last) time- We believe the risk/reward ratio has worsened palpably, since many open questions remain, including whether leronlimab could lower the mortality rate among severely ill patients in a controlled trial and if the drug is capable of generating clinically meaningful benefits among mild-to-moderate patients

Limited resources to verify the above info (quote) is not my problem.